|
| |
SIGA TechnologiesSIGA Technologies is applying bacterial genomics in the design and development of novel products for the prevention and treatment of serious infectious diseases. With broad technology platforms in both vaccines and antibiotics, SIGA's product development programs emphasize the increasingly serious problem of drug resistant bacteria.
SIGA's lead product programs focus on:
Mucosal vaccines against strep throat and sexually transmitted diseases
Commensal bacteria for the delivery of vaccines and protein therapeutics
Novel antibiotics against Gram-positive and Gram-negative bacteria
Surface Protein Expression System for the cost-effective production of proteins
SIGA's vaccine and antibiotic platforms are based on its pioneering research into the structure, function and processing of bacterial surface proteins. SIGA is leveraging these platforms through multiple strategic partners, including Wyeth-Ayerst Laboratories (the pharmaceutical division of American Home Products), and the National Institutes of Health.
| Contact Details: |
| 420 Lexington Avenue, Suite 408 |
| New York |
| New York |
| 10170 |
| United States of America |
| Tel: | (212) 672-9100 |
| Fax: | (212) 697-3130 |
| Email: | info@siga.com |
| WWW: | www.siga.com/
|
|
Loading...
|
Recent Publications by SIGA Technologies: |  |
pH-INDUCED ACTIVATION OF ARENAVIRUS MEMBRANE FUSION IS ANTAGONIZED BY SMALL-MOLECULE INHIBITORS.
The arenavirus envelope glycoprotein (GPC) mediates viral entry through... | 5th September, 2008
| Montana Biotechnology Center, The University of Montana, Missoula, MT
| J Virol. 2008 Sep 3.
DOI Direct Link |
Identification of a broad-spectrum arenavirus entry inhibitor.
Several arenaviruses, including Lassa virus (LASV), are causative agents... | 22nd August, 2008
| SIGA Technologies, Inc., Corvallis OR 97333.
| J Virol. 2008 Aug 20.
DOI Direct Link |
Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
ST-246 is a novel, potent orthopoxvirus egress inhibitor that is being... | 14th August, 2008
| SIGA Technologies, Inc., 4575 SW Research Way, Corvallis, OR 97330, USA.
| Antimicrob Agents Chemother. 2008 May;52(5):1721-7. Epub 2008 Mar 3.
DOI Direct Link |
Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
The potential threat of smallpox use in a bioterrorist attack has... | 16th April, 2008
| SIGA Technologies, Inc., 4575 SW Research Way, Suite 230, Corvallis, OR
| J Virol. 2008 Apr;82(7):3517-29. Epub 2008 Jan 16.
DOI Direct Link |
Discovery and development of antiviral drugs for biodefense: experience of a small biotechnology company.
The unmet need for effective antivirals against potential agents of... | 9th April, 2008
| SIGA Technologies, Inc., 4575 SW Research Way Suite 230, Corvallis, OR
| Antiviral Res. 2008 Jan;77(1):1-5. Epub 2007 Aug 15.
DOI Direct Link |
→View more SIGA Technologies research publications. |
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 256 times since April 2007, the link to the organisation's website has been followed 43 times Recent Search Terms used to find this page: siga opinion | siga.com | siga | siga | Single-Dose Safety and Pharmacokinetics of ST-246, a Novel Orthopoxvirus Egress Inhibitor | SIGA TECHNOLOGIES | Vaccine, 2008, 26, 7, 933-46 | siga | siga | siga technologies | . Search for more companies in New York Search for more companies in New York This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for SIGA Technologies |
